Palvella Launches Rare Disease Awareness Campaign for Microcystic Lymphatic Malformations
Event summary
- Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign on March 10, 2026.
- The campaign aims to educate patients, caregivers, and healthcare professionals about microcystic lymphatic malformations (microcystic LMs).
- Collaborators include leading nonprofit organizations such as CaNVAS, LGDA, LE&RN, PeDRA, and VAccess.org.
- Microcystic LMs affect an estimated 30,000 diagnosed patients in the U.S., with no FDA-approved therapies available.
The big picture
Palvella's campaign underscores the growing focus on rare disease education and advocacy, a critical component for biopharmaceutical companies aiming to develop therapies for underserved patient populations. The collaboration with leading nonprofit organizations highlights the strategic importance of partnerships in advancing rare disease research and treatment options.
What we're watching
- Regulatory Progress
- Whether Palvella's QTORIN™ rapamycin can secure FDA approval for microcystic LMs, given the lack of current treatments.
- Market Expansion
- The pace at which Palvella can expand its pipeline and commercialize novel therapies for rare skin diseases and vascular malformations.
- Patient Engagement
- How effective the 'BEYOND mLM' campaign will be in raising awareness and improving outcomes for microcystic LM patients.
Our editorial coverage: